Santa Monica-based Kite, a Gilead company, agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. “In vivo therapy is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback